Ameritas Advisory Services LLC Trims Position in Johnson & Johnson $JNJ

Key Points

• Ameritas Advisory Services LLC has cut its holdings in Johnson & Johnson by 10.7%, reducing its shares to 18,726, worth approximately $2.86 million at the end of the last quarter.
• Johnson & Johnson reported earnings of $2.77 per share, surpassing estimates, with quarterly revenue reaching $23.74 billion, a 5.8% increase from the previous year.
• The company recently declared a quarterly dividend of $1.30 per share, reflecting an annualized yield of 2.8% and a payout ratio of 55.61%.

Ameritas Advisory Services LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.7% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 18,726 shares of the company's stock after selling 2,253 shares during the quarter. Ameritas Advisory Services LLC's holdings in Johnson & Johnson were worth $2,860,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Elios Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after buying an additional 67 shares in the last quarter. MBA Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares in the last quarter. Sovereign Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after buying an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its stake in Johnson & Johnson by 1.5% in the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $188.51 on Friday. The stock's fifty day moving average is $176.18 and its 200 day moving average is $162.83. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.78. The firm has a market capitalization of $453.98 billion, a PE ratio of 20.16, a PEG ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm posted $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Guggenheim raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Royal Bank Of Canada upped their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $188.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.